microbot medical - MBOT

MBOT

Close Chg Chg %
2.05 -0.05 -2.44%

Closed Market

2.00

-0.05 (2.44%)

Volume: 1.56M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: microbot medical - MBOT

MBOT Key Data

Open

$2.04

Day Range

1.95 - 2.09

52 Week Range

1.11 - 4.67

Market Cap

$134.32M

Shares Outstanding

67.16M

Public Float

67.02M

Beta

1.23

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.45

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.07M

 

MBOT Performance

1 Week
 
-6.98%
 
1 Month
 
-15.61%
 
3 Months
 
-34.85%
 
1 Year
 
78.57%
 
5 Years
 
-70.97%
 

MBOT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About microbot medical - MBOT

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

MBOT At a Glance

Microbot Medical, Inc.
175 Derby Street
Hingham, Massachusetts 02043
Phone 1-781-875-3605 Revenue 0.00
Industry Biotechnology Net Income -11,443,000.00
Sector Health Technology Employees 21
Fiscal Year-end 12 / 2025
View SEC Filings

MBOT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 6.155
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.05
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.009

MBOT Efficiency

Revenue/Employee N/A
Income Per Employee -544,904.762
Receivables Turnover N/A
Total Asset Turnover N/A

MBOT Liquidity

Current Ratio 2.365
Quick Ratio 2.365
Cash Ratio 2.243

MBOT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -159.395
Return on Equity -284.971
Return on Total Capital -314.282
Return on Invested Capital -282.125

MBOT Capital Structure

Total Debt to Total Equity 3.144
Total Debt to Total Capital 3.049
Total Debt to Total Assets 1.84
Long-Term Debt to Equity 1.161
Long-Term Debt to Total Capital 1.126
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Microbot Medical - MBOT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
76.00K 102.00K 106.00K 91.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
76.00K 102.00K 106.00K 91.00K
Depreciation
76.00K 102.00K 106.00K 91.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+11.76% +34.21% +3.92% -14.15%
Gross Income
(76.00K) (102.00K) (106.00K) (91.00K)
Gross Income Growth
-11.76% -34.21% -3.92% +14.15%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
11.28M 13.18M 9.75M 11.53M
Research & Development
6.08M 7.63M 5.62M 6.54M
Other SG&A
5.20M 5.54M 4.13M 5.00M
SGA Growth
+25.05% +16.82% -26.03% +18.31%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.11M
-
EBIT after Unusual Expense
(11.36M) (13.28M) (10.97M) (11.63M)
Non Operating Income/Expense
44.00K 113.00K 226.00K 182.00K
Non-Operating Interest Income
- 54.00K 228.00K 182.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(11.31M) (13.17M) (10.74M) (11.44M)
Pretax Income Growth
-23.38% -16.40% +18.44% -6.55%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(11.31M) (13.17M) (10.74M) (11.44M)
Minority Interest Expense
- - - -
-
Net Income
(11.31M) (13.17M) (10.74M) (11.44M)
Net Income Growth
-23.38% -16.40% +18.44% -6.55%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(11.31M) (13.17M) (10.74M) (11.44M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(11.31M) (13.17M) (10.74M) (11.44M)
EPS (Basic)
-1.5916 -1.8137 -1.0529 -0.7314
EPS (Basic) Growth
-23.55% -13.95% +41.95% +30.53%
Basic Shares Outstanding
7.11M 7.26M 10.20M 15.64M
EPS (Diluted)
-1.5916 -1.8137 -1.0529 -0.7314
EPS (Diluted) Growth
-23.55% -13.95% +41.95% +30.53%
Diluted Shares Outstanding
7.11M 7.26M 10.20M 15.64M
EBITDA
(11.28M) (13.18M) (9.75M) (11.53M)
EBITDA Growth
-25.05% -16.82% +26.03% -18.31%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 2 Current Quarters Estimate -0.08
FY Report Date 03 / 2026 Current Year's Estimate -0.34
Last Quarter’s Earnings -0.065 Median PE on CY Estimate N/A
Year Ago Earnings -0.305 Next Fiscal Year Estimate -0.33
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 1
Mean Estimate -0.08 -0.09 -0.34 -0.33
High Estimates -0.07 -0.08 -0.33 -0.33
Low Estimate -0.09 -0.09 -0.35 -0.33
Coefficient of Variance -17.68 -8.32 -4.16 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Microbot Medical in the News